4//SEC Filing
Jones David Scott 4
Accession 0001562180-24-001292
CIK 0001314102other
Filed
Feb 12, 7:00 PM ET
Accepted
Feb 13, 5:38 PM ET
Size
14.5 KB
Accession
0001562180-24-001292
Insider Transaction Report
Form 4
Jones David Scott
SVP & Chief Commercial Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2024-02-09−5,000→ 5,000 totalExercise: $0.00Exp: 2032-02-09→ Common Stock (5,000 underlying) - Exercise/Conversion
Common Stock
2024-02-09+5,000→ 48,572 total - Exercise/Conversion
Common Stock
2024-02-09+4,967→ 43,572 total - Tax Payment
Common Stock
2024-02-09$28.80/sh−1,955$56,304→ 46,617 total - Tax Payment
Common Stock
2024-02-09$28.80/sh−1,701$48,989→ 44,916 total - Exercise/Conversion
Restricted Stock Units
2024-02-09−4,967→ 0 totalExercise: $0.00Exp: 2031-02-09→ Common Stock (4,967 underlying)
Footnotes (4)
- [F1]Includes 643 shares acquired on January 31, 2024 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
- [F2]No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
- [F3]The restricted stock units will vest in three ratable annual installments beginning February 9, 2022.
- [F4]The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.
Documents
Issuer
EyePoint Pharmaceuticals, Inc.
CIK 0001314102
Entity typeother
Related Parties
1- filerCIK 0001779458
Filing Metadata
- Form type
- 4
- Filed
- Feb 12, 7:00 PM ET
- Accepted
- Feb 13, 5:38 PM ET
- Size
- 14.5 KB